Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Technology evaluation: GEM-231, Hybridon.

Pollen K F Yeung¹

¹Pharmacokinetics & Metabolism Laboratory, College of Pharmacy, Dalhousie University, Halifax, NS B3H-3J5, Canada. pollen.yeung@dal.ca

Current Opinion in Molecular Therapeutics

|July 23, 2003

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Pilot Study to Assess Adenosine 5'-triphosphate Metabolism in Red Blood Cells as a Drug Target for Potential Cardiovascular Protection.

Cardiovascular & hematological disorders drug targets·2015

Same author

Diltiazem reduces mortality and breakdown of ATP in red blood cell induced by isoproterenol in a freely moving rat model in vivo.

Metabolites·2014

Same author

Effect of acute exercise on cardiovascular hemodynamic and red blood cell concentrations of purine nucleotides in hypertensive compared with normotensives rats.

Therapeutic advances in cardiovascular disease·2013

Same author

Comparing pharmacokinetics and metabolism of diltiazem in normotensive Sprague Dawley and Wistar Kyoto rats vs. spontaneously hypertensive rats in vivo.

Drug metabolism and drug interactions·2011

Same author

Exercise improves hemodynamic profiles and increases red blood cell concentrations of purine nucleotides in a rodent model.

Therapeutic advances in cardiovascular disease·2010

Same author

Pharmacokinetics and metabolism of diltiazem following multiple doses: comparing normotensive rat vs. hypertensive rat models in vivo.

Drug metabolism letters·2009

GEM-231, an investigational hybrid oligonucleotide, is being evaluated for cancer treatment. Clinical trials are underway combining GEM-231 with chemotherapy drugs like paclitaxel, docetaxel, and irinotecan.

Area of Science:

Oncology
Molecular Therapeutics
Clinical Pharmacology

Background:

GEM-231 (HYBO-165) is an 18-mer hybrid oligonucleotide developed by Hybridon.
It is under investigation as a potential therapeutic agent for cancer treatment.

Purpose of the Study:

To evaluate the safety and efficacy of GEM-231 in combination therapies for solid tumors.
To determine appropriate dosages for GEM-231 in Phase I/II clinical trials.

Main Methods:

Phase I/II dose-escalation trials involving GEM-231.
Combination therapy studies with paclitaxel, docetaxel, and irinotecan (CPT-11).
Initiation of trials in patients diagnosed with solid tumors.

Main Results:

Related Experiment Videos

Ongoing Phase I/II trials of GEM-231 with paclitaxel and docetaxel as of March 2002.

Initiation of a Phase I/II trial combining GEM-231 with irinotecan in patients with solid tumors.

Planning for Phase II trials to commence in 2003.

Conclusions:

GEM-231 is progressing through clinical development for cancer treatment.
Combination strategies with standard chemotherapeutics are being explored.
Further clinical evaluation in Phase II trials is planned.